Hear Mel tell his story of
how it all started.

Craig Kennedy

CEO

Craig has deep insight into the wound care market combined with a proven track record of building businesses. He served as CEO of MolecuLight, a Canadian wound care start-up that developed and launched an imaging device capable of detecting bacteria in wounds.

He also served as VP, Business Development and Strategy for UK-based Systagenix, an established provider of advanced wound care (AWC) products. When the firm was purchased by Acelity, a global AWC company, Craig was a key player facilitating the acquisition.

More recently, Craig was named a 10 Best Inspiring CEO of 2020 for his global approach, commercial credibility, customer focus, and clear communication across all stakeholder groups.

Jane Clark

VP, Global Marketing and Clinical Affairs

Jane’s career spanning both commercial and clinical environments uniquely positions her to deeply understand Inotec customers. With an MSc in Wound Healing and Tissue Repair and having worked as a Tissue Viability Specialist in the UK’s National Health Service (NHS), Jane’s 14 years clinical experience combined with +15 years of commercial experience affords her extensive knowledge of clinicians’ needs.

As Senior Marketing Director for Acelity, Jane was responsible for the management and strategic direction of the Negative Pressure Wound Therapy (NPWT) and Advanced Wound Dressings (AWD) portfolios across Europe, Middle East, and Asia-Pacific which had combined revenues of +$350M. Jane also served in senior marketing and clinical roles for Systagenix and Johnson & Johnson.

Recently recognized in the Top 25 Women Leaders in Medical Devices of 2021, Jane was awarded for her specialized knowledge, overall impact on Inotec, dynamism and strong motivation.

Kathryn Hohenberger

VP, Americas

Kathryn has a proven reputation for building wound care businesses with +25 years of experience in the healthcare and medical device industry. Notably, she worked for 3 years as Vice President, USA of Acelity/Systagenix significantly growing Systagenix through to acquisition by KCI, one of the largest advanced wound care (AWC) companies worldwide.

Her leadership was realized at Hill-Rom company serving in senior executive positions, including VP Clinical Division where she focused on improving patient outcomes across the care continuum. Kathryn's clinical background and passion for patient advocacy fuels her desire to exceed customer expectations—her top priority is serving both the healthcare teams and the patients being treated.

Nick Howard

Director, Strategy

After successfully commercializing NATROX^® O₂ in the UK market, Nick’s current focus is driving the strategic direction of the NATROX^® Wound Care brand by supporting its global market opportunities and the development of new technologies.

Before joining the company, Nick was Global Category Director for Acelity, managing several market-leading global wound care brands, growing them to a revenue of +$120M.

His career in healthcare spans 24 years and includes roles in the NHS, SCA Hygiene Products (Essity) and healthcare communications, plus international sales & marketing positions for Mölnlycke Healthcare and ConvaTec, leading medical solutions companies.

Sandy Fliri-Marx

Director, Human Resources

Sandy brings +20 years of HR experience, with more than half her career in leading Life Sciences firms such as Amgen, Abcam, and Novartis. She has a strong interest in health care on both a professional and personal level, serving as a volunteer at The Hospice Biographers, and supporting students move from education into employment in Life Sciences with Form the Future.

Sandy has developed successful HR strategies for organizations of varying sizes with locations across the globe. Her role is pivotal for Inotec’s expansion. She is responsible for developing HR strategies and system, managing employee relations and recruiting and onboarding staff.

Bruce Geltman

Director, US Strategic Accounts

Prior to joining Inotec, Bruce was a medical, cardiac device and kidney dialysis services professional with St. Jude Medical/Abbott Vascular, Johnson and Johnson and DaVita, maintaining national sales and corporate accounts responsibilities. Prior to moving into the medical device arena in 2005, Bruce was in the telecommunications industry at Corning, Inc. with responsibilities that ranged from Sales Engineering to VP of Sales and Marketing. Bruce drives organizational relevance partnership & growth via planning, analysis, strategic relationships and decisive execution.

Lamine Guendil

General Manager, Asia

Lamine manages Inotec Asia, our Southeast Asian sales headquarters based in Kuala Lumpur, Malaysia. His team’s focus is to provide innovative therapies for people suffering chronic wounds across the region.

Originally serving as a NATROX^® distributor, after Lamine witnessed the positive healing impact our products had on wounds first-hand, he later decided to join the Inotec family. Lamine brings an intense passion for sales, a strong customer-focus, and a creative approach.

Abdul Alshareef

Quality Manager

Abdul’s focus is to ensure strict adherence to quality standards and performance. He brings +19 years international experience working in the pharmaceutical and medical device manufacturing industries throughout the UK, USA, Europe, and Middle East.

Abdul has served in upper management positions in Quality and Manufacturing for firms like Vectura Limited, the Lindal Group, and Schivo Medical. He has an MBA degree and Lean Six Sigma Black Belt certification and extensive expertise in continuous improvement.

David Fernández

Sales Director, EMEA & LATAM

David brings over 14 years of experience in medical devices across a range of areas including dental, respiratory, and diagnostic. Although his main experience is in sales, he has also held positions in product marketing, giving him a well-rounded understanding of customer needs.

With a proven track record of setting up distributor networks in the medical device field across EMEA, David plays a pivotal role maximising business opportunities and bringing a stronger overall focus to the EMEA and LATAM regions.

Dr. Adrian Parton, MBE

Chairman

Adrian Parton is a Director of Objective Imaging Ltd (Hardware Software Automation business), AB-Polyblok Ltd (novel dementia drug), Toxibact Ltd (novel antimicrobial) and Chairman/Owner of Ivy House Country House Hotel. He has a PhD in Molecular Virology and has been in industry for the last 25 years. He has successfully grown technology based businesses from concept through to production and into multi-national businesses.

Michael Clancy

Non-Executive Director

Michael Clancy has 35 years’ experience in marketing, sales and general management within European medical devices with specialist knowledge and experience within the medical beds, pressure redistribution and wound care sectors. He is currently non-executive director at Medstrom Ltd and Inotec AMD Limited.

Pierre Socha

Non-Executive Director

Pierre Socha is an early-stage technology investor with Amadeus Capital Partners. He invests in digital health, medical technologies, autonomous systems, augmented reality, cyber security and artificial intelligence. He currently sits on the boards of Doctify, Repositive, Lumeon, PhoreMost and Congenica.

Alessandro Piga

Non-Executive Director

Founding Partner and Managing Director of Techwald Holdings. Alessandro brings with him extensive international experience in leadership and board positions at public and private companies within the Health Care and Medical Technology Industry. He is also Director of SoniVie and Bendit Technologies, two Israeli MedTech developers and is a member of the Italian Angels for Growth association. Prior to Techwald his career spans senior roles in the MedTech sectors including amongst others being J&J’s MD for Italy and Cordis (Cardinal Health company) MD for Italy.

Andy Round

Non-Executive Director

Andy is an experienced investor, company director and accomplished scientist with a PhD in Biochemistry from Leeds University. A life sciences expert, he has been responsible for healthcare deals at Praetura Ventures and continues to provide more than money to existing and prospective portfolio companies. Prior to joining Praetura Ventures, Andy led on equity investments for Maven, SPARK Impact and has invested from balance sheet, VCT and EIS funds.